News
2021.04.26
COREE and Sichuan University Enter into a “Joint Research and Platform Development of Nucleic Acid Vaccine Vectors” Agreement
COREE, an innovation bio-healthcare investment company, entered into an agreement with China’s Sichuan University regarding the “Joint Research and Platform Development of Nucleic Acid Vaccine Vectors.”
Nucleic Acid Vector Research Agreement Conclusion between COREE and Sichuan University / Photography provided by COREE
The signing ceremony was held in the main building at Sichuan University, with the participation of Director Chin Yong, Vice-director Huh Chin, Professor Soon Shin of Hwashi College of Pharmacy at Sichuan University, Dr. Seo Yeong, in charge of COREE’s China R&D, Senior Superintendent Lo Jeon Hwa of COREE Therapeutics Beijing, etc. Through this agreement, COREE has come to begin a joint research effort for the development of scientific technology of future innovative vaccine by fusing the knowledge and technology of the research team of Sichuan University’s College of Pharmacy.
COREE, with its title from the term referring to “Korea” in the ancient French map from the 1700s, is a global company specializing in bio and healthcare, with headquarters in Hong Kong and corporate locations in Beijing and Shanghai, China, Milano, Italy, Los Angeles, USA, and Pohang, Korea, continues investment for research and new technology development in the bio and healthcare fields, and it has various pipelines domestically and abroad.
COREE, beginning with a joint research agreement for medical care with Italy’s Policlinico Universitario Agostistino Gemelli, one of the three gastroenterology hospitals selected by 
Clinical Research Team for “COREE Metabolic Disease Prevention Specialized Fund” of Peking Union Medical Foundation / Photography provided by COREE
Life Ofmom App 2020 Good Design Selection / Photograph provided by COREE
COREE also joint-established a medical foundation fund committee with Peking Union Medical College Hospital in November 2019. In March 2021, COREE and the Peking Union Medical College Hospital’s medical foundation acquired medical permission from the China Human Gene Resource Management Office regarding the “Model Research of the Prediction of Complex Occurrences of Gestational Diabetes Mellitus (GDM)” to discover marker of the high occurrence of GDM and begin actual clinical research to actualize the innovative digital prevention treatment through this. As the permission for the clinical research by the China Human Gene Resource Management Office is the approval of digital diagnosis clinical testing by China’s agency of authority, the plan is to establish a GDM prediction model that can diagnose with precision according to the analytical algorithm by integrating personal life medical information data and pathological analysis data through this clinical research. COREE and the Peking Union Medical College Hospital are establishing a digital treatment environment in China by applying the digital remote treatment beta version on the Life Ofmom application.
China’s Sichuan University / Image source: Baidu
Established in 1896, China’s Sichuan University is one of the top colleges in China, and the Hwashi College of Pharmacy, established in 1918 as the first official pharmaceutical regular course of higher education institution, has the best medical clinical research currently in China. Especially, Professor Soon Shin, while leading this COREE research, is the highest authority of “High-efficiency Nucleic Acid Vaccine Vector and Drug Transport System Establishment” and is working as the vice editor-in-chief of J. Controlled Release, the official journal of CRS, and plans to research on the most appropriate vector that can resolve the problem occurring in the transport process of nucleic acid in the human body through the joint research with COREE.
Also, COREE is pursuing the establishment of Korea’s first digital medical therapy apparatus industrial ecosystem in COREE Pohang, which was established recently in Pohang, Gyeongbuk, and currently has 3 digital medical groups, a bio-engineering platform, beneficial bacteria, and various other global pipelines with continuous investment in Ofmom, the subsidiary company that develops powdered milk and infant products.